VolitionRx Expands Nu.Q® NETs Assay into Hidradenitis Suppurativa
Event summary
- VolitionRx published clinical study data on January 27, 2026, demonstrating Nu.Q® NETs assay's use in managing Hidradenitis Suppurativa (HS).
- The assay is CE-Marked for clinical use in 30 European countries, including the UK.
- Study suggests Nu.Q® NETs can classify HS severity and monitor treatment response, addressing unmet needs in precision medicine.
- Total Addressable Market for Nu.Q® NETs indications estimated at $3.8 billion.
The big picture
VolitionRx's expansion into Hidradenitis Suppurativa with its Nu.Q® NETs assay highlights the growing trend of precision medicine in chronic disease management. The $3.8 billion TAM for NETosis-associated indications underscores the strategic importance of this development, particularly as healthcare systems seek cost-effective, personalized solutions for complex immune-mediated disorders. This move could position VolitionRx as a key player in the diagnostics space, provided it can secure broader regulatory approvals and commercial adoption.
What we're watching
- Market Expansion
- Whether VolitionRx can leverage this data to secure regulatory approvals and commercial partnerships beyond Europe.
- Clinical Validation
- The pace at which additional studies confirm Nu.Q® NETs' utility across other chronic conditions.
- Competitive Positioning
- How this positions VolitionRx against competitors in the growing precision medicine diagnostics space.
Related topics